Clinical Trial Confirms: Nasal Spray Safely Treats Recurrent Abnormal Heart Rhythms

A new study has demonstrated that etripamil, a home-administered nasal spray, safely and effectively treats PSVT, a condition causing rapid heart rhythms, potentially minimizing hospital visits and invasive procedures.

Investigators from Weill Cornell Medicine conducted a clinical trial that demonstrated a nasal spray could successfully and safely treat recurrent abnormal rapid heart rhythms at home, without a physician’s assistance. Published in the Journal of the American College of Cardiology, the study presents real-world evidence that the experimental drug, etripamil, is both safe and effective for a broad range of patients managing recurrent paroxysmal supraventricular tachycardia (PSVT) episodes. This could significantly reduce the need for hospital visits and more invasive treatments.

The study is the latest in a series of studies by lead author Dr. James Ip, professor of clinical medicine at Weill Cornell Medicine and a cardiologist at NewYork-Presbyterian/Weill Cornell Medical Center, and colleagues to demonstrate the potential of nasal spray calcium-channel blocker etripamil as an at-home treatment PSVT. Dr. Ip received compensation as a steering committee member for Milestone Pharmaceuticals, the maker of etripamil and sponsor of the trial.